Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Cash Flow: 2016-2025

Historic Net Cash Flow for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to -$83.7 million.

  • Rhythm Pharmaceuticals' Net Cash Flow rose 26.31% to -$83.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 123.87%. This contributed to the annual value of $29.2 million for FY2024, which is 143.27% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Net Cash Flow is -$83.7 million, which was down 380.45% from $29.8 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Net Cash Flow peaked at $108.5 million during Q2 2024, and registered a low of -$113.5 million during Q3 2024.
  • In the last 3 years, Rhythm Pharmaceuticals' Net Cash Flow had a median value of -$4.3 million in 2023 and averaged -$6.8 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 193.85% in 2023, then skyrocketed by 1,668.92% in 2024.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Net Cash Flow stood at -$33.1 million in 2021, then crashed by 73.32% to -$57.4 million in 2022, then surged by 92.48% to -$4.3 million in 2023, then soared by 1,040.74% to $40.6 million in 2024, then climbed by 26.31% to -$83.7 million in 2025.
  • Its last three reported values are -$83.7 million in Q3 2025, $29.8 million for Q2 2025, and $17.0 million during Q1 2025.